Peptides for weight loss are lab-made versions of hormones your body naturally produces to regulate appetite, blood sugar, and fat storage. The most effective ones mimic a gut hormone called GLP-1, and they’ve produced dramatic results in clinical trials, with some helping people lose 15% to 21% of their body weight over about a year and a half. Two are currently FDA-approved specifically for chronic weight management: semaglutide (sold as Wegovy) and tirzepatide (sold as Zepbound).
How Weight Loss Peptides Work
Your gut releases a hormone called GLP-1 after you eat. It signals your brain that you’re full, slows down how quickly food leaves your stomach, and helps regulate blood sugar by boosting insulin and lowering glucagon. The problem is that natural GLP-1 breaks down in minutes. Weight loss peptides are engineered to last much longer, keeping those fullness signals active for days instead of moments.
These medications work on two fronts. In the brain, they act on appetite-control centers to reduce hunger and change how you respond to food cues. Many people describe it as the constant “food noise” in their head going quiet. In the body, they slow gastric emptying (so you feel satisfied longer after meals), improve how your body handles insulin, and shift your metabolic balance toward using stored energy.
Newer peptides go further by targeting more than one hormone at once. Tirzepatide, for instance, activates receptors for both GLP-1 and another gut hormone called GIP. This dual action appears to amplify weight loss beyond what GLP-1 alone achieves. Triple-action peptides targeting GLP-1, GIP, and glucagon pathways are also in development.
FDA-Approved Options and How They Compare
Semaglutide (Wegovy)
Semaglutide was the first GLP-1 peptide to reshape the weight loss landscape. In the STEP clinical trials, which enrolled thousands of participants and ran for 68 weeks, people taking semaglutide lost roughly 12% to 15% more of their body weight than those on placebo, depending on the trial. A longer two-year study confirmed the results held up, with a 12.6% greater weight reduction compared to placebo at 104 weeks. It’s injected once a week under the skin.
Tirzepatide (Zepbound)
Tirzepatide, the dual-action peptide, has shown even larger effects. In its pivotal 72-week trial published in the New England Journal of Medicine, people taking the highest dose (15 mg) lost an average of 20.9% of their body weight, compared to 3.1% for placebo. Even the lowest dose (5 mg) produced a 15% average reduction. About 30% of participants on the lowest dose hit the 20%-or-more weight loss mark, a threshold once considered achievable only through surgery.
Liraglutide (Saxenda)
Liraglutide was the earlier generation GLP-1 peptide approved for weight management. It requires daily injections rather than weekly ones, and the results are more modest: roughly 4% to 6% more weight loss than placebo over 56 weeks. It’s still available but has largely been overtaken by semaglutide and tirzepatide in both effectiveness and convenience.
Other Peptides You’ll See Marketed
Beyond the FDA-approved medications, you’ll encounter a range of peptides promoted for fat loss through clinics, online sellers, and social media. The most common include growth hormone-releasing peptides like CJC-1295 and ipamorelin, as well as a fragment called AOD9604. These occupy a very different category from GLP-1 medications.
CJC-1295 and ipamorelin work by stimulating your pituitary gland to release more growth hormone, which can influence fat metabolism and muscle maintenance. However, their evidence base for weight loss in humans consists mostly of user-reported experiences rather than controlled clinical trials. People who use them typically report improved sleep, body composition changes, and recovery benefits, but there’s no large-scale trial data comparable to what exists for semaglutide or tirzepatide.
AOD9604 is a synthetic fragment of human growth hormone designed to mimic its fat-burning effects without affecting blood sugar or growth. Mouse studies have shown it can reduce body weight and body fat over 14 days of treatment, and it appears to work by increasing the body’s sensitivity to fat breakdown. But the jump from promising mouse data to proven human therapy is enormous, and AOD9604 has no FDA approval for weight loss. If someone is offering it as an equivalent alternative to approved peptides, that’s a red flag.
What Taking These Peptides Looks Like
FDA-approved weight loss peptides are given as subcutaneous injections, typically in the abdomen, thigh, or upper arm using a pre-filled pen. The needles are small, similar to what people with diabetes use for insulin. Most people get comfortable with the process within the first few weeks.
You don’t start at the full dose. Semaglutide begins at 0.25 mg once weekly and increases every four weeks through several steps before reaching the maintenance dose of 2.4 mg. This gradual ramp-up takes about 16 to 20 weeks and exists specifically to let your body adjust and minimize side effects. Tirzepatide follows a similar escalation pattern over 4 to 20 weeks, with target maintenance doses of 5, 10, or 15 mg weekly. If you’re struggling with side effects at a given dose, your prescriber can pause the increase for an extra four weeks before moving up.
Weight loss is not immediate. Most people notice reduced appetite within the first few weeks, but significant weight changes typically become visible after two to three months as the dose increases. The major clinical trials measured outcomes at 68 to 72 weeks, so these are long-term treatments, not quick fixes.
Common Side Effects
Gastrointestinal issues are by far the most frequent side effects. Nausea affects up to 50% of people taking GLP-1 peptides, making it the single most common complaint. Diarrhea is also very common. Vomiting, constipation, abdominal pain, and indigestion occur less frequently but are still reported regularly. These effects are directly tied to how the peptides slow gastric emptying, and they tend to be worst during dose increases, then improve as your body adapts.
The more serious concern people ask about is pancreatitis. Some studies have found a modestly elevated risk of pancreatic inflammation with GLP-1 medications, while several large meta-analyses have found no significant increase. The FDA and European Medicines Agency reviewed the evidence jointly and concluded that a causal link hasn’t been established. That said, the possibility hasn’t been completely ruled out, so persistent severe abdominal pain while taking these medications warrants prompt medical attention.
Cost and Access
Price is one of the biggest barriers. Zepbound carries a list price of $1,086.37 per monthly fill. Wegovy is in a similar range. Without insurance coverage, these are the prices you’ll pay at a pharmacy, plus any dispensing fees. Lilly has introduced a direct-to-patient vial option for Zepbound at lower price points ranging from $299 to $699 per month depending on the dose, which bypasses some of the traditional pharmacy markup.
Insurance coverage varies widely. Some plans cover these medications for people who meet specific BMI thresholds (generally 30 or above, or 27 with a weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol). Many plans still classify them as lifestyle drugs and exclude them entirely.
The Compounding Problem
The high cost and supply shortages of brand-name peptides have fueled a booming market in compounded versions, where specialty pharmacies create their own formulations. This is where things get risky. The FDA has specifically warned that some compounded semaglutide products use salt forms of the drug, such as semaglutide sodium or semaglutide acetate, that are chemically different from the active ingredient in the approved medication. The agency has stated plainly that it has no information on whether these salt forms behave the same way in the body, and it is not aware of any lawful basis for using them in compounding.
This matters because peptides are complex molecules. Small differences in formulation can affect how they’re absorbed, how long they last, and whether they work at all. A compounded peptide sold at a fraction of the brand-name price may contain a different active ingredient than what’s in the studied, approved product. That’s not a generic equivalent; it’s an untested variation.